Back to search results
NCT07640555

Evaluation of [¹⁸F]MODAG-009 PET Imaging in Synucleinopathies

Recruiting
EARLY_PHASE1Ages 50–80InterventionalDiagnostic
MODAG GmbH
~13 participants
Updated 2026-06-10 on ClinicalTrials.gov
What's tested:[¹⁸F]MODAG-009 PET imaging

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Standard Uptake Value Ratios (SUVR)
Measured over Up to 3 hours after tracer injection.
+2 more outcomes measured

Conditions

Multiple System Atrophy (MSA)
Healthy Adult
Parkinson Disease

Explore related trials

Multiple System AtrophyParkinson DiseaseSodium-Dependent Dopamine Transporter

Where it's being run

1 sites across 1 states
Connecticut1

Who to contact

Johannes Levin, MD
[email protected]
475-318-8250 (24 hours)
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Exclusion

All Cohorts:

What this trial measures

  • Standard Uptake Value Ratios (SUVR)Up to 3 hours after tracer injection.

    To evaluate Standard Uptake Value Ratios (SUVR) in brain regions from \[18F\]MODAG-009 in participants with PD.

  • Standard Uptake Value Ratios (SUVR)Up to 3 hours after tracer injection.

    To evaluate Standard Uptake Value Ratios (SUVR) in brain regions from \[18F\]MODAG-009 in participants with MSA.

  • Standard Uptake Value Ratios (SUVR)Up to 3 hours after tracer injection.

    To evaluate Standard Uptake Value Ratios (SUVR) in brain regions from \[18F\]MODAG-009 in HC participants.